Price
Financials
Standalone, Rs crore| Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 4.95 | 4.10 | 8.21 | 7.65 | 8.16 | 4.49 | 10.32 | 9.66 | 32.60 |
| Expenses | 4.56 | 2.99 | 6.74 | 6.26 | 8.73 | 4.07 | 9.95 | 9.32 | 29.74 |
| Operating Profit | 0.39 | 1.11 | 1.47 | 1.39 | -0.57 | 0.42 | 0.37 | 0.34 | 2.86 |
| OPM % | 7.88% | 27.07% | 17.90% | 18.17% | -6.99% | 9.35% | 3.59% | 3.52% | 8.77% |
| Other Income | 0.00 | 0.00 | 0.02 | 0.11 | 0.22 | 0.22 | 0.25 | 0.00 | 0.00 |
| Interest | 0.25 | 0.32 | 0.33 | 0.38 | 0.41 | 0.41 | 0.44 | 0.07 | 0.00 |
| Depreciation | 0.11 | 0.08 | 0.08 | 0.08 | 0.05 | 0.07 | 0.03 | 0.07 | 0.21 |
| Profit before tax | 0.03 | 0.71 | 1.08 | 1.04 | -0.81 | 0.16 | 0.15 | 0.20 | 2.65 |
| Tax % | 33.33% | 21.13% | 35.19% | 25.96% | -25.93% | 18.75% | 33.33% | 25.00% | 32.83% |
| Net Profit | 0.02 | 0.55 | 0.69 | 0.77 | -0.61 | 0.12 | 0.10 | 0.15 | 1.78 |
| EPS in Rs | 0.06 | 1.67 | 0.69 | 0.55 | -0.44 | 0.09 | 0.07 | 0.11 | 1.17 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales | 16.62 | 11.54 | 11.21 | 12.31 | 15.80 | 14.81 | 42.26 |
| Expenses | 15.71 | 10.68 | 10.44 | 9.73 | 14.97 | 14.02 | 39.06 |
| Operating Profit | 0.91 | 0.86 | 0.77 | 2.58 | 0.83 | 0.79 | 3.20 |
| OPM % | 5.48% | 7.45% | 6.87% | 20.96% | 5.25% | 5.33% | 7.57% |
| Other Income | 0.01 | 0.00 | 0.00 | 0.02 | 0.32 | 0.47 | 0.00 |
| Interest | 0.41 | 0.44 | 0.51 | 0.65 | 0.79 | 0.85 | 0.07 |
| Depreciation | 0.31 | 0.26 | 0.22 | 0.17 | 0.13 | 0.10 | 0.28 |
| Profit before tax | 0.20 | 0.16 | 0.04 | 1.78 | 0.23 | 0.31 | 2.85 |
| Tax % | 20.00% | 25.00% | 25.00% | 30.34% | 26.09% | 25.81% | 31.93% |
| Net Profit | 0.16 | 0.12 | 0.03 | 1.25 | 0.16 | 0.22 | 1.93 |
| EPS in Rs | 0.48 | 0.36 | 0.09 | 1.26 | 0.11 | 0.16 | 1.27 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | 30% | 51% | 185% | ||
| Compounded Profit Growth | % | 74% | 16% | 777% | ||
| Stock Price CAGR | % | % | 34% | 100% | ||
| Return on Equity | % | 4% | 4% | 8% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 3.30 | 3.30 | 3.30 | 9.95 | 13.95 | 13.95 | 15.25 |
| Reserves | 3.94 | 4.06 | 4.10 | 0.73 | 8.89 | 9.11 | 13.12 |
| Borrowings | 4.53 | 5.52 | 5.30 | 4.93 | 6.83 | 2.57 | 0.21 |
| Other Liabilities | 2.24 | 1.01 | 0.86 | 2.07 | 2.73 | 2.15 | 6.36 |
| Total Liabilities | 14.01 | 13.89 | 13.56 | 17.68 | 32.40 | 27.78 | 34.94 |
| Fixed Assets | 2.13 | 1.87 | 1.65 | 1.51 | 1.38 | 1.28 | 2.87 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.57 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 11.88 | 12.02 | 11.91 | 16.17 | 31.02 | 24.93 | 32.07 |
| Total Assets | 14.01 | 13.89 | 13.56 | 17.68 | 32.40 | 27.78 | 34.94 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | -1.46 | -1.00 | 0.21 | -1.66 | -7.42 | 0.21 | 0.70 |
| Cash from Investing Activity | -0.02 | 0.00 | 0.00 | -0.03 | 0.32 | -1.11 | -0.30 |
| Cash from Financing Activity | 1.51 | 0.98 | -0.22 | 1.68 | 8.87 | -5.10 | 1.01 |
| Net Cash Flow | 0.03 | -0.02 | -0.01 | 0.00 | 1.77 | -5.99 | 1.41 |
| Free Cash Flow | -1.48 | -1.00 | 0.21 | -1.69 | -7.42 | -1.36 | 0.40 |
| CFO/OP | -156% | -112% | 29% | -43% | -888% | 35% | 49% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 159.66 | 241.96 | 253.64 | 166.04 | 131.22 | 210.97 | 137.85 |
| Inventory Days | 56.13 | 83.17 | 93.82 | 44.74 | 125.41 | 119.50 | 70.03 |
| Days Payable | 49.48 | 33.11 | 26.34 | 60.49 | 54.71 | 39.02 | 32.59 |
| Cash Conversion Cycle | 166.31 | 292.03 | 321.13 | 150.28 | 201.91 | 291.44 | 175.29 |
| Working Capital Days | 110.91 | 204.32 | 211.64 | 45.07 | 76.23 | 374.61 | 168.16 |
| ROCE % | 4.87% | 4.30% | 17.17% | 4.51% | 4.20% | 10.77% |
| Jun 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 90.45% | 64.52% | 64.52% | 64.09% | 63.89% | 63.89% | 63.89% | 63.65% | 59.57% | 56.65% |
| Public | 9.55% | 35.48% | 35.48% | 35.91% | 36.11% | 36.11% | 36.11% | 36.35% | 40.43% | 43.35% |
| No. of Shareholders | 21 | 659 | 585 | 581 | 551 | 492 | 476 | 462 | 397 | 382 |
Fundamentals
Market Cap₹ 82.1 Cr.
Current Price₹ 53.8
Stock P/E42.6
Book Value₹ 18.6
ROCE10.8 %
ROE7.51 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)185%
Compounded Profit Growth (TTM)777%
Standalone figures.
Valuation
Market capRs 56 Cr
Enterprise valueRs 61 Cr
P/E (TTM)44.97x
Price to book5.26x
Price to sales4.57x
EV / EBITDA23.51x
EV / EBIT25.15x
EV / sales4.96x
Earnings yield2.22%
Profitability
Operating margin (excl. other income)20.96%
Operating margin (incl. other income)21.12%
EBITDA margin21.12%
Pre-tax margin14.46%
Net profit margin10.15%
ROE13.83%
ROCE17.17%
ROA8.00%
ROE, 3-year average5.29%
ROCE, 3-year average8.78%
ROA, 3-year average3.03%
ROIC (approx.)10.87%
Tax rate30.34%
Other income / net worth0.19%
Growth
Sales growth (latest year)9.81%
Profit growth (latest year)4066.67%
Sales CAGR, 3 years-9.52%
Profit CAGR, 3 years98.43%
Per share
EPS (TTM)Rs 1.26
EPS (latest year)Rs 1.26
EPS, 3-year averageRs 0.57
Book value per shareRs 10.73
Sales per shareRs 12.37
Cash flow per shareRs -1.67
Free cash flow per shareRs 0.40
Efficiency
Asset turnover0.70x
Fixed asset turnover8.15x
Inventory turnover8.26x
Inventory days44 days
Debtor days166 days
Debtors turnover2.20x
Creditor days33 days
Cash conversion cycle175 days
Working capital days168 days
Leverage
Total debtRs 5 Cr
Cash and bankRs 0 Cr
Net debtRs 5 Cr
Debt to equity0.46x
Net debt / EBITDA1.88x
Interest coverage3.74x
Owners' fund to total sources60.41%
Debt to assets27.88%
Cash flow
Cash from Operating Activity (latest year)Rs -2 Cr
Cash from Investing Activity (latest year)Rs -0 Cr
Cash from Financing Activity (latest year)Rs 2 Cr
Free cash flow (latest year)Rs 0 Cr
FCFE (approx.: FCF + change in debt)Rs 0 Cr
Cash from ops / profit, 5 years-2.22x
Statement figures
Net sales (TTM)Rs 12 Cr
Net sales (latest year)Rs 12 Cr
Operating profit excl. other income (latest year)Rs 3 Cr
Other income (TTM)Rs 0 Cr
EBITDA (TTM)Rs 3 Cr
PBDT (TTM)Rs 2 Cr
Profit before tax (TTM)Rs 2 Cr
Tax (latest year)Rs 1 Cr
Net profit (TTM)Rs 1 Cr
Net profit (latest year)Rs 1 Cr
Depreciation (TTM)Rs 0 Cr
Interest (TTM)Rs 1 Cr
Cost of goods sold (latest year)Rs 7 Cr
Total expenditure (latest year)Rs 10 Cr
Total income (latest year)Rs 12 Cr
Share capitalRs 10 Cr
ReservesRs 1 Cr
Shareholders' fundsRs 11 Cr
Total assetsRs 18 Cr
Net blockRs 2 Cr
ReceivablesRs 6 Cr
InventoryRs 1 Cr
Other liabilitiesRs 2 Cr
Shares outstanding (crore)0.99
Ownership
Promoter holding56.65% (-7.24 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 45.0 is at the 11th percentile of its own 2.3-year range
(median 144.9, low 31.8, high 232.2).
P/B 5.26 is at the 95th percentile (median 3.19).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | VILINBIO | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | +2.7% | -2.8% | +5.5 pts |
| 1 month | +26.4% | -6.8% | +33.2 pts |
| 3 months | +25.0% | -7.6% | +32.6 pts |
| 6 months | +66.4% | +0.4% | +66.0 pts |
| 1 year | +100.0% | -9.9% | +109.9 pts |
| 2 years | +179.7% | -13.6% | +193.3 pts |
| 3 years | +161.6% | +14.2% | +147.4 pts |
Red flags
F-score 4 of 7| explain | Weak cash conversion Cash from operations was -175% of net profit over the last 3 years |
| explain | High accruals Profit exceeded operating cash by 16% of total assets in 2026 |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Mar 2026Sales ₹33 Cr +299.5% vs Mar 2024.
Net profit ₹2 Cr +391.8%.
Against our estimate for Mar 2026: sales +97.4%, profit +755.0% big beat.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Less than 100 unique PAN traded in previous 30 daysMandatory Market making period in SME scrip is overSME scrip is not regularly traded
Quick answers
What is the market cap of Vilin Bio Med Ltd?
Vilin Bio Med Ltd (VILINBIO) has a market capitalisation of Rs 82.1 Cr. at the 2026-09-30 close.
What is the P/E ratio of Vilin Bio Med Ltd?
Vilin Bio Med Ltd trades at a P/E of 42.6 on trailing twelve-month profit, at the 2026-09-30 close.
What were Vilin Bio Med Ltd's latest quarterly results?
In the Mar 2026 quarter, Vilin Bio Med Ltd sales was Rs 33 Cr (+299.5% vs Mar 2024) and net profit was Rs 2 Cr.
What is the 52-week high and low of Vilin Bio Med Ltd?
The 52-week high is Rs 60.95 and the 52-week low is Rs 18.95.